{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:31:34Z","timestamp":1793046694434,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-023-10333-2","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T03:05:49Z","timestamp":1689735949000},"page":"1307-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lipoprotein(a) and heart failure: a systematic review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Lavalle-Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"10333_CR1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118:3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"10333_CR2","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N et al (2021) Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. Eur J Heart Fail 23:352\u2013380.\u00a0https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.022","DOI":"10.1016\/j.cardfail.2021.01.022"},{"key":"10333_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/pharmaceutics15031002","volume":"15","author":"JF Ndiaye","year":"2023","unstructured":"Ndiaye JF, Nekka F, Craig M (2023) Understanding the mechanisms and treatment of heart failure: quantitative systems pharmacology models with a focus on SGLT2 inhibitors and sex-specific differences. Pharmaceutics 15:1002. https:\/\/doi.org\/10.3390\/pharmaceutics15031002","journal-title":"Pharmaceutics"},{"key":"10333_CR4","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.ijcard.2012.11.065","volume":"168","author":"S Khatibzadeh","year":"2013","unstructured":"Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A (2013) Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol 168:1186\u20131194. https:\/\/doi.org\/10.1016\/j.ijcard.2012.11.065","journal-title":"Int J Cardiol"},{"key":"10333_CR5","doi-asserted-by":"publisher","first-page":"3491764","DOI":"10.1155\/2020\/3491764","volume":"2020","author":"MM Jawi","year":"2020","unstructured":"Jawi MM, Frohlich J, Chan SY (2020) Lipoprotein(a) the Insurgent: A new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids 2020:3491764. https:\/\/doi.org\/10.1155\/2020\/3491764","journal-title":"J Lipids"},{"key":"10333_CR6","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR et al (2022) Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 42:e48\u2013e60. https:\/\/doi.org\/10.1161\/ATV.0000000000000147","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10333_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7775\/rac.v90.i3.20516","volume":"90","author":"W Masson","year":"2022","unstructured":"Masson W, Lobo L, Barbagelata L, Bagnati R, Oberti P, Falconi M et al (2022) High lipoprotein(a) levels and risk of aortic valve stenosis related clinical event: a systematic review. Rev Argent Cardiol 90:215\u2013221. https:\/\/doi.org\/10.7775\/rac.v90.i3.20516","journal-title":"Rev Argent Cardiol"},{"key":"10333_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11906-021-01161-6","volume":"23","author":"NC Ward","year":"2021","unstructured":"Ward NC, Nolde JM, Chan J, Carnagarin R, Watts GF, Schlaich MP (2021) Lipoprotein(a) and hypertension. Curr Hypertens Rep 23:44. https:\/\/doi.org\/10.1007\/s11906-021-01161-6","journal-title":"Curr Hypertens Rep"},{"key":"10333_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","volume":"349","author":"C Lamina","year":"2022","unstructured":"Lamina C, Ward NC (2022) Lipoprotein(a) and diabetes mellitus. Atherosclerosis 349:63\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.016","journal-title":"Atherosclerosis"},{"key":"10333_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","volume":"4","author":"PR Kamstrup","year":"2016","unstructured":"Kamstrup PR, Nordestgaard BG (2016) Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail 4:78\u201387. https:\/\/doi.org\/10.1016\/j.jchf.2015.08.006","journal-title":"JACC Heart Fail"},{"key":"10333_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.5114\/aoms.2016.59875","volume":"13","author":"Y Wang","year":"2017","unstructured":"Wang Y, Ma H, Yang J, Chen Q, Lu L, Zhang R (2017) Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease. Arch Med Sci 13:1078\u20131085. https:\/\/doi.org\/10.5114\/aoms.2016.59875","journal-title":"Arch Med Sci"},{"key":"10333_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","volume":"262","author":"A Agarwala","year":"2017","unstructured":"Agarwala A, Pokharel Y, Saeed A, Sun W, Virani SS, Nambi V et al (2017) The association of lipoprotein(a) with incident heart failure hospitalization: atherosclerosis risk in communities study. Atherosclerosis 262:131\u2013137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.05.014","journal-title":"Atherosclerosis"},{"key":"10333_CR13","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1161\/ATVBAHA.118.311220","volume":"38","author":"BT Steffen","year":"2018","unstructured":"Steffen BT, Duprez D, Bertoni AG, Guan W, Tsai MY (2018) Lipoprotein(a)-related risk of heart failure is evident in caucasians but not in other racial\/ethnic groups: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 38:2498\u20132504. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311220","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10333_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5935\/abc.20190120","volume":"113","author":"J Yan","year":"2019","unstructured":"Yan J, Pan Y, Xiao J, Ma W, Li L, Zhong M et al (2019) High level of lipoprotein(a) as predictor for recurrent heart failure in patients with chronic heart failure: a cohort study. Arq Bras Cardiol 113:197\u2013204. https:\/\/doi.org\/10.5935\/abc.20190120","journal-title":"Arq Bras Cardiol"},{"key":"10333_CR15","doi-asserted-by":"publisher","unstructured":"Shitara J, Kasai T, Konishi H, Endo H, Wada H, Doi S et al (2019) Impact of lipoprotein (a) levels on long-term outcomes in patients with coronary artery disease and left ventricular systolic dysfunction. Circ J 83:1047\u20131053. https:\/\/doi.org\/10.1253\/circj.CJ-18-0970","DOI":"10.1253\/circj.CJ-18-0970"},{"key":"10333_CR16","doi-asserted-by":"publisher","unstructured":"Wu B, Zhang Z, Long J, Zhao H, Zeng F (2022) Association between lipoprotein (a) and heart failure with reduced ejection fraction development. J Clin Lab Anal 36:e24083. https:\/\/doi.org\/10.1002\/jcla.24083","DOI":"10.1002\/jcla.24083"},{"key":"10333_CR17","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/ehf2.13933","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, Liu J, Shen J, Chen Y, He L, Li M et al (2022) Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction. ESC Heart Fail 9:2399\u20132406. https:\/\/doi.org\/10.1002\/ehf2.13933","journal-title":"ESC Heart Fail"},{"key":"10333_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","volume":"156","author":"S Arya","year":"2021","unstructured":"Arya S, Kaji AH, Boermeester MA (2021) PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg 156:789\u2013790. https:\/\/doi.org\/10.1001\/jamasurg.2021.0546","journal-title":"JAMA Surg"},{"key":"10333_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"10333_CR20","doi-asserted-by":"publisher","unstructured":"Melita H, Manolis AA, Manolis TA, Manolis AS (2022) Lipoprotein (a) and cardiovascular disease: a missing link for premature atherosclerotic heart disease and\/or residual risk. J Cardiovasc Pharmacol 79:e18\u2013e35.https:\/\/doi.org\/10.1097\/FJC.0000000000001160","DOI":"10.1097\/FJC.0000000000001160"},{"key":"10333_CR21","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","volume":"42","author":"M Rauchhaus","year":"2003","unstructured":"Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R et al (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42:1933\u20131940. https:\/\/doi.org\/10.1016\/j.jacc.2003.07.016","journal-title":"J Am Coll Cardiol"},{"key":"10333_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1054\/jcaf.2002.0804216","volume":"8","author":"TB Horwich","year":"2022","unstructured":"Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC (2022) Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8:216\u2013224. https:\/\/doi.org\/10.1054\/jcaf.2002.0804216","journal-title":"J Card Fail"},{"key":"10333_CR23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, B\u00f6hm M, Cleland JG, Cornel JH et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248\u20132261. https:\/\/doi.org\/10.1056\/NEJMoa0706201","journal-title":"N Engl J Med"},{"key":"10333_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R et al (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(08)61240-4","journal-title":"Lancet"},{"key":"10333_CR25","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab804","volume":"43","author":"HD White","year":"2022","unstructured":"White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE et al (2022) Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 43:1554\u20131565. https:\/\/doi.org\/10.1093\/eurheartj\/ehab804","journal-title":"Eur Heart J"},{"key":"10333_CR26","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.3390\/ijms24065927","volume":"24","author":"C St\u0103tescu","year":"2023","unstructured":"St\u0103tescu C, Anghel L, Benchea LC, Tudurachi BS, Leonte A, Z\u0103voi A et al (2023) A systematic review on the risk modulators of myocardial infarction in the \u201cyoung\u201d-implications of lipoprotein (a). Int J Mol Sci 24:5927. https:\/\/doi.org\/10.3390\/ijms24065927","journal-title":"Int J Mol Sci"},{"key":"10333_CR27","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1002\/ejhf.2333","volume":"42","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treat-ment of acute and chronic heart failure of the European society of cardiology (esc) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1002\/ejhf.2333","journal-title":"Eur Heart J"},{"key":"10333_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.hlc.2017.05.117","volume":"26","author":"S Prabhu","year":"2017","unstructured":"Prabhu S, Voskoboinik A, Kaye DM, Kistler PM (2017) Atrial fibrillation and heart failure - cause or effect? Heart Lung Circ 26:967\u2013974. https:\/\/doi.org\/10.1016\/j.hlc.2017.05.117","journal-title":"Heart Lung Circ"},{"key":"10333_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1161\/CIRCEP.113.001378","volume":"7","author":"S Mora","year":"2014","unstructured":"Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM (2014) Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol 7:612\u2013619. https:\/\/doi.org\/10.1161\/CIRCEP.113.001378","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10333_CR30","first-page":"18316","volume":"9","author":"W-J Li","year":"2016","unstructured":"Li W-J, M-H, Yin R, Cui Y-Q, Yin L, Jiang S-L, et al (2016) The prospective effect of lipoprotein(a) on new-onset atrial fibrillation in patients with chronic heart failure. Int J Clin Exp Med 9:18316\u201318323","journal-title":"Int J Clin Exp Med"},{"key":"10333_CR31","doi-asserted-by":"publisher","unstructured":"Garg PK, Guan W, Karger AB, Steffen BT, O'Neal W, Heckbert SR et al (2020) Lp(a) (lipoprotein [a]) and risk for incident atrial fibrillation: multi-ethnic study of atherosclerosis. Circ Arrhythm Electrophysiol 13:e008401. https:\/\/doi.org\/10.1161\/CIRCEP.120.008401","DOI":"10.1161\/CIRCEP.120.008401"},{"key":"10333_CR32","doi-asserted-by":"publisher","unstructured":"Cairns BJ, Coffey S, Travis RC, Prendergast B, Green J, Engert JC et al (2017) A replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data. Circulation 135:1181e3. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026103","DOI":"10.1161\/CIRCULATIONAHA.116.026103"},{"key":"10333_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.numecd.2023.01.025","volume":"33","author":"W Masson","year":"2023","unstructured":"Masson W, Barbagelata L, Oberti P, Falconi M, Lavalle-Cobo A, Corral C et al (2023) High lipoprotein(a) levels and mitral valve disease: A systematic review. Nutr Metab Cardiovasc Dis 33:925\u2013933. https:\/\/doi.org\/10.1016\/j.numecd.2023.01.025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10333_CR34","doi-asserted-by":"publisher","first-page":"1205475","DOI":"10.3389\/fcvm.2023.1205475","volume":"10","author":"SK Masenga","year":"2023","unstructured":"Masenga SK, Kirabo A (2023) Hypertensive heart disease: risk factors, complications and mechanisms. Front Cardiovasc Med 10:1205475. https:\/\/doi.org\/10.3389\/fcvm.2023.1205475","journal-title":"Front Cardiovasc Med"},{"key":"10333_CR35","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","volume":"112","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Anavekar N, Skali H, McMurray JJV, Swedberg K, Yusuf S et al (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112:3738\u20133744. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.561423","journal-title":"Circulation"},{"key":"10333_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al (2021) CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37:531\u2013546. https:\/\/doi.org\/10.1016\/j.cjca.2021.01.017","journal-title":"Can J Cardiol"},{"key":"10333_CR37","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"10333_CR38","doi-asserted-by":"publisher","unstructured":"Tsimikas S, Marcovina SM (2022) Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. J Am Coll Cardiol 80:934\u2013946. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.019","DOI":"10.1016\/j.jacc.2022.06.019"},{"key":"10333_CR39","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J 43:3925\u20133946. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10333-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10333-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10333-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T04:15:31Z","timestamp":1697170531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10333-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["10333"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10333-2","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"16 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}